Weekly Issue — 2026-04-05

The shift is visible on three fronts at once. Real-world comparative studies are quantifying what clinic-day intuition already suspected — that semaglutide outperforms its older siblings on the metrics patients track. A novel cAMP-biased agonist, ecnoglutide, has cleared a phase 3 head-to-head against dulaglutide. And fixed-ratio combinations are beginning to fold GLP-1 peptides into basal-insulin regimens with results that would have looked implausible two years ago.

For the data-minded reader, this is the moment the class stops behaving like a monolith.

Head-to-head GLP-1 trials are rare; head-to-head GLP-1 data from routine clinical care is rarer still. A multicenter retrospective study across Chinese endocrinology clinics enrolled adults with Type 2 diabetes who initiated semaglutide 1.0 mg, dulaglutide 1.5 mg, or liraglutide 1.8 mg between 2022 and 2024. After 1:1 propensity-score matching, semaglutide produced a 0.27% greater HbA1c reduction than dulaglutide and a 0.39% greater reduction than liraglutide, with higher rates of reaching glycemic targets and no meaningful divergence in safety signals.

Two caveats matter. This was retrospective, not randomized — propensity matching narrows confounding but cannot eliminate it. And the long-term cardiovascular and mortality projections in the paper come from a simulation model (UKPDS Outcomes Model 2.1) rather than observed events. Still, the within-class hierarchy the study describes — semaglutide > dulaglutide ≈ liraglutide — matches what the randomized literature has hinted at, and it is the kind of comparative evidence the wearable-and-CGM crowd has been asking for.

The most genuinely novel entry is ecnoglutide. Unlike semaglutide and its relatives, which engage the GLP-1 receptor as balanced agonists, ecnoglutide is biased: it preferentially activates the intracellular cAMP signaling pathway and recruits less β-arrestin. In receptor pharmacology this is a meaningful distinction — β-arrestin recruitment is associated with receptor desensitization and downregulation, so a cAMP-biased agonist could, in theory, deliver more sustained signaling per dose.

The EECOH-2 trial put that theory to a 52-week test. Across 52 hospitals in China, 623 adults with Type 2 diabetes on metformin monotherapy were randomized 1:1:1 to weekly subcutaneous ecnoglutide at 0.6 mg or 1.2 mg, or dulaglutide 1.5 mg. The primary endpoint was HbA1c change at week 32, with non-inferiority margins set at 0.4% for both ecnoglutide doses and superiority sought for the 1.2 mg arm. The mean baseline HbA1c was a high 8.40%, leaving plenty of room to move.

What ecnoglutide is not, yet, is a proven semaglutide-beater — that trial has not been published. What it is, is the first commercially advancing piece of evidence that engineering receptor bias into GLP-1 peptides is a viable design strategy rather than a slide-deck concept.

The third front is formulation. HR17031 is a fixed-ratio combination of a basal insulin analogue (INS068) and a GLP-1 agonist called noiiglutide, delivered as a single injection. A phase 2 multicenter trial randomized 455 Chinese adults with Type 2 diabetes uncontrolled on oral agents to HR17031, INS068 alone, or noiiglutide alone, and measured HbA1c change over 26 weeks.

The combination won decisively. HR17031 cut HbA1c by 2.4%, versus 1.5% for basal insulin alone and 1.7% for the GLP-1 alone — superiority over both components, with p < 0.0001 for each comparison. More than 80% of HR17031 patients reached HbA1c below 7.0%, and nearly three-quarters crossed below 6.5%. Crucially, the combination produced no weight gain, in contrast to a 2.0 kg gain on basal insulin alone, and the GI side effects that dog GLP-1 monotherapy — nausea, diarrhea, vomiting — were roughly halved relative to noiiglutide alone.

The mechanistic logic is elegant: the GLP-1 component offsets the appetite and weight effects of basal insulin while the insulin component handles the fasting glucose that GLP-1s address less aggressively. The clinical logic is even simpler — one injection instead of two.

Even as new molecules arrive, the incumbent keeps generating evidence. A 2025 systematic review and meta-analysis examined once-weekly subcutaneous semaglutide 2.4 mg specifically in Asian populations with overweight or obesity — a group historically underrepresented in the trials that built the drug's reputation. Five RCTs covering 2,614 participants met the inclusion criteria, all judged at low risk of bias.

The pooled results were substantial. Semaglutide 2.4 mg produced a mean body-weight reduction of 8.20% versus placebo, alongside a 6.47 cm reduction in waist circumference and a 3.22 kg/m² drop in BMI. Heterogeneity was high (I² around 84%), which is the price of pooling across diverse Asian cohorts and study designs, but the direction and magnitude of effect were consistent.

For readers who track HbA1c trends on continuous monitors and weigh themselves on Bluetooth scales, the practical implication of the 2026 data is this: the GLP-1 you start on is no longer a foregone conclusion, and within a year or two the choice will plausibly include a biased agonist, a fixed-ratio combination, and second-generation single agents alongside the familiar names. None of that changes the fundamental rule of this category — these are prescription peptides with real metabolic and gastrointestinal effects, and the right molecule, dose, and titration schedule is a decision to make with a clinician, not a forum thread.

What it does change is the question worth asking at the next appointment. A year ago that question was whether to start a GLP-1 at all. Increasingly, it is which one — and why.

The study in question followed more than 40,000 adults in China's Kailuan cohort for roughly 14 years, tracking who went on to develop aortic valve calcification (AVC) — the gradual stiffening and calcium build-up on the valve that controls blood leaving the heart — and who died during the follow-up window. Compared with people in the lowest quartile of TyG, those in the highest quartile had a 40% higher risk of incident AVC and a 16% higher risk of death. Inflammation, measured by high-sensitivity C-reactive protein (hs-CRP), explained part — but not most — of the connection.

That is a real signal in a serious dataset. It is also not a verdict. This is observational work in a single regional cohort, and a higher hazard ratio is not the same as a personal prognosis. But for women navigating perimenopause — when triglycerides drift up, fasting glucose creeps, and insulin sensitivity can quietly erode — it is the kind of finding that earns a closer look.

The TyG index is a back-of-the-envelope proxy for insulin resistance, built from two numbers most of us already get tested: fasting triglycerides and fasting glucose. The gold-standard way to measure insulin resistance is a clamp study, which involves IVs, hours of monitoring, and a research lab. Nobody is doing that at their annual physical. TyG was proposed as a stand-in: cheap, calculable, derived from labs you probably already have on file.

Why those two numbers? When cells stop responding well to insulin, the liver tends to pump out more triglyceride-rich particles and blood glucose tends to run higher. Pair them, and you get a rough read on whether your metabolism is working harder than it should to keep things in range — even if your fasting glucose alone still looks 'normal.'

Aortic valve calcification used to be filed under 'wear and tear' — an unlucky consequence of getting older. The current understanding is messier and more interesting: AVC behaves like an active, inflammation-driven process that shares biological turf with atherosclerosis. Insulin resistance and chronic low-grade inflammation are both plausible accelerants.

The Kailuan analysis tested that idea directly. Researchers asked whether hs-CRP — a standard inflammation marker — sat in the causal middle between TyG and valve calcification. It did, but only partially: hs-CRP mediated about 12.65% of the TyG–AVC association and 15.81% of the TyG–mortality association. Translation: inflammation is part of the story, not the whole story. Whatever else insulin resistance is doing to valves, it is mostly doing through other pathways the study did not measure.

Let's be honest about the limits. This is one large cohort, observational, conducted in a Chinese industrial workforce that skews male and is not a stand-in for a 44-year-old American woman in perimenopause. The researchers adjusted for the usual suspects — age, sex, smoking, blood pressure, lipids — but observational studies cannot rule out residual confounding. Higher TyG often travels with higher body weight, worse sleep, more sedentary time, and a diet heavy in refined carbohydrates. Some of the 'TyG effect' is almost certainly those companions.

It also does not prove that lowering your TyG number lowers your valve risk. No one has run that trial. What the study supports is the more modest claim the authors themselves make: TyG is a meaningful, low-cost signal that something metabolic may be off, and the people in the highest quartile deserve closer attention. The authors conclude that more stringent glucose and lipid control will benefit individuals at higher risk of AVC — a sensible recommendation that does not require any new prescription.

For women in the 35–50 window, the practical read is this: if your triglycerides have been creeping up alongside a fasting glucose that is technically 'fine' but no longer flattering, that combination is worth a conversation, not a panic. Bring the actual numbers to your clinician. Ask whether your insulin resistance picture warrants more than a glance at LDL.

The most honest framing for a finding like this one is also the least dramatic: a number you can already see on your lab report may carry a little more information than we used to give it credit for. That is not a revolution. It is a nudge to look at the whole metabolic panel — and the whole person — rather than the one or two values that have historically gotten all the attention.

MAFLD is the rebrand of what many of us still call fatty liver disease. The name change matters: it ties the condition explicitly to metabolic risk — obesity, type 2 diabetes, insulin resistance — rather than framing it as a mystery diagnosis or a drinking problem. According to the 2026 update, adults with those metabolic risk factors should be assessed for it, and liver ultrasound is the recommended first-line test for spotting hepatic steatosis, the fat accumulation inside liver cells that defines the disease.

That's a meaningful shift. For years, fatty liver was treated as an incidental finding — something noted on a scan and shrugged off unless enzymes were wildly elevated. The new framing treats it as a screen-able, modifiable condition that sits squarely inside the same conversation as blood sugar, blood pressure, and waist circumference.

The liver has always been a metabolic organ — it just rarely gets star billing next to the pancreas or the thyroid. A 2026 perspective in Chronic Diseases and Translational Medicine describes the liver as a major regulator of systemic cardio-renal-metabolic health, which is a polite way of saying: when the liver is inflamed or fatty, the downstream effects radiate outward into heart, kidney and metabolic risk.

That same review makes a striking point about sex-chromosome biology. In Turner syndrome (monosomy X), population studies show two- to sixfold higher odds of raised liver enzymes, steatotic liver disease, advanced fibrosis, and even hepatocellular malignancy compared with age-matched controls. In Klinefelter syndrome (47,XXY), the prevalence of MASLD — the closely related steatotic-liver diagnosis — reaches approximately 45%, with testosterone deficiency, visceral fat, and systemic inflammation acting as key drivers. The authors argue this suggests sex-chromosome dosage itself, independent of sex hormones, may shape liver disease risk — an important caveat for anyone who assumes liver health is gender-neutral.

The honest read: this is a perspective review, not a randomized trial. But it lands inside a bigger pattern — the liver as a quietly central node in metabolic health, with risk distributions that are far from uniform across populations.

Dietary fat quality is one of the few levers in this space that is both modifiable and measurable. A 2026 systematic review and meta-analysis in Food Science & Nutrition looked specifically at canola oil in adults with non-alcoholic fatty liver disease (NAFLD, the older and overlapping label). Across three randomized trials and 220 participants, canola oil intake was associated with significant reductions in ALT and AST — two of the main liver enzymes used to flag hepatic inflammation — with effect sizes of −0.47 and −0.51 respectively. Triglycerides also dropped, though with substantial heterogeneity across studies.

What the data did not show is just as important. HDL cholesterol didn't move significantly, and neither did gamma-glutamyl transferase (GGT). Three trials is a small evidence base, and the authors are careful with their conclusions. This isn't a green light to start chugging canola oil; it's a signal that, within an otherwise reasonable diet, the type of fat you cook with may nudge liver markers in the right direction. That's a moderate-strength finding, and it deserves moderate-strength language.

For a wellness audience that has been told for years that seed oils are the villain of the metabolic story, this is a useful counterpoint. The trial-level evidence in people with diagnosed fatty liver points the other way. It doesn't end the debate — but it complicates the confident TikTok version of it.

Here's where the 2026 clinical update gets practical. If you're an adult with obesity, type 2 diabetes, or other metabolic risk factors, the recommendation is to be assessed for MAFLD — typically starting with ultrasound, then layering on noninvasive testing for liver fibrosis if steatosis is found. Management focuses on addressing health risk behaviors, treating comorbidities, and — for the smaller subset who progress to cirrhosis — surveillance for hepatocellular carcinoma.

None of that is dramatic. There is no headline-grabbing drug yet that resolves MAFLD reliably for most people. The interventions that move the needle are the ones already in the metabolic-health playbook: weight reduction where clinically indicated, improved glycemic control, more movement, better dietary patterns. The liver responds to the same inputs as the rest of your metabolism — which is the optimistic reframing buried inside this so-called silent epidemic.

The story underneath all of this is hopeful, in a moderate, evidence-respecting way. A condition that touches roughly a third of adults has, until recently, lived in clinical blind spots. Now it has a name that connects it to metabolic health, a first-line test that's widely available, and a small but growing body of dietary evidence. That's not a cure. It's something better: a clearer map of a problem we can actually do something about.